iOnctura

🗞 Breaking News! 🗞 We are thrilled to announce we have successfully closed our 80M Euro Series B financing round. 📣 Led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures , Inkef Capital, Vi Partners, Schroders Capital and 3B Future Health Fund I & II, this funding highlights a shared vision for the potential of our portfolio of precision oral small molecules.   This significant funding will:   🚀 Accelerate development of #roginolisib for the treatment of #uvealmelanoma through a randomized Phase II study 🚀 Broaden development of roginolisib for other cancer indications, including randomized Phase II studies in #NSCLC and primary #myelofibrosis 🚀 Progress #cambritaxestat and IOA-359 programs   Watch this space as we kick off a number of Phase II studies later in 2024.   Thank you to the team, investors and collaborators who continue to support and drive iOnctura forward. Link to press release in comments ⬇ #financing #oncology #drugdevelopment

In a continuation of our 'Meet the Team' series, today we are introducing organizational linchpin and superheroine of the office... 🌟 Head of Office Operations and HR Szilvia Bonhoure 🌟 Szilvia is an operational powerhouse. She owns our admin processes, supports our company's growth and still has time to look after us all. Luckily for us her exemplary logistical skills get applied to team building exercises as well as company operations. As a result Team iOnctura performs as well in cookery school, curling championships and wine tasting as we do nagivating the world of drug development 💊 #meettheteam #biotech #teamworkmakesthedreamwork

It isn't just us that thinks the future's bright for the PI3K field 🔦 Pleased to see DelveInsight Business Research LLP thinks its "stunning" in their latest report 🌞 We are contributing to reignited interest in PI3Kd through our allosteric modulator #roginolisib, with its unique binding mode and biochemical properties 💊 Next generation PI3Ka inhibitors are similarly improving on prior generations of therapies - we will be keeping an eye on Scorpion Therapeutics's results at ESMO next month We are also excited for the next steps for Kazia Therapeutics Limited's paxalisib, the only PI3Ka inhibitor able to penetrate the blood brain barrier and which reported positive results in its Phase 2/3 study in #glioblastoma last month The future really is bright ✴ 👉 See the full report here: https://lnkd.in/eYFngeft

The Swiss Venture Capital Report's half year update makes for interesting reading 🗞 Biotech performed well and with surveyed investors reporting ‘dry powder’; i.e. funds available for investment, we hope this trend is set to continue. iOnctura's Series B of 76.5M CHF was the second largest of the period 👏 👉 Read the full report here: https://lnkd.in/eYpAudxe

In today's episode of the 'Meet our Team' series we continue with the clinical trend of recent weeks by introducing you to... 🌟 VP of Clinical Sciences Paramjit Kaur 🌟 In the past year since joining us Paramjit has very quickly made her mark; honing our clinical operations and strategy, liaising between research and clinical to increase our efficiencies and abilities and providing strategic input to commercial activities. We are lucky to be benefiting from her decades of experience and are thrilled she is part of our journey going forward 🤩 #meettheteam #biotech #teamworkmakesthedreamwork

iOnctura CMO Michael L. and Head of Research Giusy Di Conza were interviewed in July's Medical Technology magazine reporting on practice-changing research in oncology presented at ASCO 2024. Read their insights here... 👉 https://lnkd.in/e8Z6A8NC

📰 Thank you to MedNous (Evernow Publishing Ltd) for the great interview featuring our CEO and co-founder, Catherine Pickering, in its recent July-August 2024 edition! Great to see #iOnctura highlighted in Mednous' 'Small company, big theme' section focusing on how we are pursuing drug resistance.   💡 Make sure to check out the article on page 5 for an insightful read!   #cancer #oncology #biotech #lifesciences

Last week in our "Meet Our Team" series we introduced our clinical powerhouse with CMO Michael L..... Next up is supporting superstar, the one and only.... 🌟 VP of clinical development and operations Tracey Hammett 🌟 Tracey is a fountain of knowledge on all things drug development and clinical trials gained from her decades of experience in large pharma and CROs 💊 What she doesn't know about clinical trials could be written on a (very small) post-it 🔠 Before her pharmaceutical career Tracey was a registered nurse which gives her great empathy with the patients we treat, and their families 👩⚕️ When she isn't managing the complex strands of our clinical trial strategy and operations, you will find her enjoying the great outdoors, hiking, walking her dog and maybe even giving the occasional goat a cuddle. 🐐 😂 #meettheteam #biotech #teamworkmakesthedreamwork

🌟 Meet the Team Series 🌟 Today's member of Team iOnctura is our amazing, one-and-only, Chief Medical Officer Michael L. 👏 Michael brings a wealth of knowledge and experience to our company gained from decades of experience in companies such as Eli Lilly and Company, AstraZeneca and Incyte. Although his drug development experience is unparalleled, it's his ability to empathise with patients and clinicans alike that sets him apart. This skill of understanding the patient journey and making sure we keep the patient at the heart of our strategy motivates all of us, everyday. ⏰ When he's not busy at work, Michael can be found enjoying art, picking fine wines for the iOnctura team to try and learning new languages (he's currently on 5 and counting...!) #meettheteam #biotech #teamworkmakesthedreamwork

In today's episode of the 'Meet our Team' series we would like to introduce you to... 🌟 Head of Research Giusy Di Conza 🌟 Joining iOnctura in 2022 with over 12 years of experience in onco-immunology and tumor-stroma interactions, Giusy has accelerated non-clinical research into our targets of interest 🎯 She is passionate about developing promising cancer therapies that aim to have direct impacts on patients’ lives. In addition to her pipetting skills, Giusy is also a dab hand at chili growing and her dance skills (particularly when on a moving boat) are a force to be reckoned with 🕺